Chandra Mohan | Medicinal Chemistry | Excellence in Research

Published on by Top Pharmaceutical

Chandra Mohan | Medicinal Chemistry | Excellence in Research

Assoc. Prof. Dr. Chandra Mohan at K R Mangalam University, Gurugram, India.

Assoc. Prof. Dr. Chandra Mohan is an accomplished researcher and educator in Inorganic Chemistry with a Ph.D. in chemical sensors 🧪. Currently serving at K.R. Mangalam University, he has over 12 years of academic experience 📚. His expertise spans green chemistry, nanomaterials, and environmental sustainability 🌱. With global collaborations 🌍, 12 authored/edited books 📘, and 15 book chapters, he is a driving force in sustainable science. Dr. Mohan has guided multiple Ph.D. scholars 🎓, led funded projects, and organized international conferences. His dynamic contributions continue to inspire innovation, education, and impactful research across borders.

Publication Profile 

Google Scholar

Education

Assoc. Prof. Dr. Chandra Mohan holds a Ph.D. in Inorganic Chemistry 🧪 from Guru Gobind Singh Indraprastha University, specializing in chemical sensors. He is currently a Post-Doctoral Scholar at Amity University, Dubai 🏙️. He also earned an MBA in HR + IT in 2024 📊. Dr. Mohan has completed an M.Phil. in acid catalysts from the University of Delhi 🧫 and an M.Sc. in Applied Chemistry from MDSU 🧬. His academic journey began with a B.Sc. in PCM 📘 and included a diploma in computer programming 💻. He also qualified GATE (Chemistry) in 2013 ✅, showcasing his scholarly depth.

Experience

Assoc. Prof. Dr. Chandra Mohan brings over 13 years of dedicated academic experience to the field of chemistry education 🧪. Since August 2023, he has served as an Associate Professor at K. R. Mangalam University, Gurugram 🏫. Prior to that, he held the position of Assistant Professor at the same university from 2013 to 2023, contributing a solid decade of teaching, research, and academic leadership 📚. His early academic journey began at HMRITM College, affiliated with GGSIPU, Delhi, where he served as Assistant Professor from January 2010 to February 2011 👨‍🔬, marking the foundation of his scholarly path.

Awards 

Assoc. Prof. Dr. Chandra Mohan has been widely recognized for his academic brilliance and social contributions 🎓🌍. He received the Advanced Materials Award from IAAM, Sweden 🇸🇪 in 2024 and the Best Researcher Award from ScienceFather in 2023 🔬. His passion for innovation earned him the Young Researcher Award by IARC, Kenya 🇰🇪 in 2022 and Best Paper Award at DAM2IC the same year 📄. With consecutive Legal Awareness Awards (2020–2022) and honors for Social Services and Youth Engagement 🇮🇳, he exemplifies academic excellence and civic responsibility. He also received the Young Faculty Award in 2016 & 2018.

Research Focus 

Assoc. Prof. Dr. Chandra Mohan specializes in Inorganic Chemistry, with a strong research focus on chemical sensors, coordination chemistry, nanocomposites, and sustainable environmental materials 🌱🧪. His expertise spans Schiff base metal complexes, clay mineral applications, and green chemistry approaches for drug design 💊 and water treatment 💧. He actively explores polymer composites, ion-selective electrodes, and biocompatible catalysts for eco-friendly industrial solutions 🌍. His interdisciplinary collaborations extend to bioplastics, AI in sustainability, and agricultural innovations 🌾, highlighting his dedication to solving real-world problems through chemistry and materials science.

Publication Top Notes

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile 

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus 

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

  • Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction
  • A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*
  • A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction
  • Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*
  • Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*
  • A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**
  • Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.
  • A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold
  • Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization
  • Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications
  • A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous
  • Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine
  • Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials
  • Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Prof. Maysoon Al-Haideri| Drug Discovery |Best Researcher Award

Published on by Top Pharmaceutical

Prof. Maysoon Al-Haideri|Drug Discovery|Best Researcher Award

Prof. Maysoon Al-Haideri at University oh Kurdistan Hewlêr,Iraq

PROFILE  

scopus 

 

Early Academic Pursuits 🎓

Dr. Al-Haideri began her educational journey at Baghdad University, where she completed her B.Sc. in Pharmacy in 1973. She demonstrated early promise and a strong interest in clinical analysis, leading her to pursue an Advanced Diploma in Clinical Analysis from Baghdad University between 1977 and 1979. Her academic curiosity and pursuit of excellence took her to the United States, where she attended Columbia University in the City of New York, earning a Master of Arts (M.A.) in 1983, followed by an M.Phil. in Pathology in 1985. Her dedication and passion culminated in a Ph.D. in Pathology from Columbia University in 1987, marking the beginning of an illustrious career in clinical research and academia.

Professional Endeavors 🩺

Dr. Al-Haideri’s professional career began in Iraq, where she gained practical experience and took on leadership roles in several medical institutions. She completed a traineeship in Clinical Hematology, Clinical Biochemistry, Medical Microbiology, Parasitology, and Infectious Diseases at the Ministry of Health in Baghdad from 1974 to 1975. Following this, she served as the Director of the Clinical Laboratory at Abo-Alkhaseab Hospital in Basrah (1975-1976) and Chief of the Clinical Biochemistry and Hematology Divisions at Al-Khadmia Teaching Hospital in Baghdad (1976-1981). During this time, she was also responsible for student supervision and training, highlighting her commitment to fostering the next generation of healthcare professionals.

From 1981 to 1982, Dr. Al-Haideri took on a national role as the Director of Quality Control and Standardization for all public clinical laboratories in Iraq, ensuring the consistent application of best practices in clinical analysis. Her leadership and expertise were further recognized when she undertook a traineeship in infertility at the Ministry of Health in Baghdad in 1982, signaling her growing influence in medical diagnostics and reproductive health.

In the United States, Dr. Al-Haideri continued her impressive trajectory, completing a postdoctoral fellowship at North Shore University Hospital, Manhasset, New York (1987-1988), followed by research positions at Long Island Jewish Medical Center (1988-1990) and Albert Einstein College of Medicine, Bronx, New York (1989-1991). During this time, she held the title of Instructor of Immunology, Rheumatology, and Allergy. Dr. Al-Haideri’s academic and research career reached new heights when she joined Columbia University’s College of Physicians and Surgeons, where she worked as an NIH Postdoctoral Research Trainee (1991-1994), eventually becoming an Associate Research Scientist and Assistant Professor (1994-2004).

Contributions and Research Focus 🔬

Dr. Al-Haideri’s research has primarily focused on clinical pathology, immunology, rheumatology, and allergy. Her work has been instrumental in enhancing the understanding of immunological responses in various pathological conditions. She has been actively involved in numerous research projects, often collaborating with leading medical institutions in both the U.S. and Iraq.

Her role as Director of Quality Control and Standardization in Iraq’s Ministry of Health laid the groundwork for the development of national policies aimed at ensuring the accuracy and reliability of clinical laboratory diagnostics across the country. In the U.S., her work at prestigious institutions like Columbia University and Albert Einstein College of Medicine helped advance the field of immunology, particularly in relation to autoimmune diseases.

Accolades and Recognition 🏆

Dr. Al-Haideri’s work has been widely recognized through various awards and honors. She received NIH Grant Awards from 1991 to 1994, which supported her groundbreaking research in immunology and pathology. Her academic excellence was also acknowledged at Columbia University, where she was awarded Graduate Research Assistantships.

Her commitment to medical education and healthcare development in Iraq earned her numerous accolades, including being named Employee of the Year at Hawler Medical University in Erbil, Kurdistan in 2012. Additionally, she received letters of appreciation from the Minister of Higher Education and Scientific Research in the Kurdistan region, as well as from the President of Hawler Medical University and several deans of colleges at the university for her contributions to education and healthcare.

Impact and Influence 🌍

Dr. Al-Haideri has had a profound impact on medical education and healthcare both in Iraq and abroad. As a leader in various institutions, she has played a critical role in shaping the medical education system in the Kurdistan Region of Iraq. Her tenure as Dean of the College of Health Sciences at Hawler Medical University (2014-2018) and Director of Quality Assurance (2010-2015) helped set new standards for academic excellence and institutional leadership in the region.

Her influence extends beyond academia. Dr. Al-Haideri has been an active member of numerous professional societies, including the American Society for Biochemistry and Molecular Biology and the American Heart Association, further cementing her status as a respected expert in her field. Her involvement in international organizations, such as the International Institute of Education in New York, reflects her commitment to global collaboration and knowledge exchange.

Legacy and Future Contributions 🔮

Dr. Maysoon Tahir Al-Haideri’s legacy is one of dedication to advancing medical knowledge, improving healthcare systems, and fostering academic excellence. Her work has had a lasting impact on the clinical and academic landscapes in Iraq, particularly in the Kurdistan region, where she has influenced generations of healthcare professionals through her leadership roles at Hawler Medical University and Cihan University-Erbil.

As she continues her work as the Director of the Pharmacy Program at the University of Kurdistan Hewler, Dr. Al-Haideri remains committed to mentoring students and contributing to the development of the healthcare sector in the region. Her achievements serve as an inspiration to future generations of scientists, educators, and healthcare professionals, ensuring her legacy will endure for years to come.

🎓Publication 

Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice

  • Authors   :Al-Haideri, M.
  • Journal    :Clinics and Research in Hepatology and Gastroenterology
  • Year         :2024

Functional and financial analysis of an inclined step solar desalination using phase change nanomaterials

  • Authors   : Mahal, A., Al-Haideri, M., Alkhouri, A., Obaidullah, A.J., Duan, M.
  • Journal    :Water Science and Technology
  • Year         :2024

Tuning the optoelectronic properties of selenophene-diketopyrrolopyrrole-based non-fullerene acceptor to obtain efficient organic solar cells through end-capped modification

  • Authors   :Ijaz, R., Waqas, M., Mahal, A., … Alatawi, N.S., Aloui, Z.
  • Journal    :Journal of Molecular Graphics and Modelling,
  • Year         :2024

Rational designing of phenothiazine dioxide based hole transporting materials for efficient perovskite solar cells

  • Authors   : Hanan, M., Umair, Mahal, A., … Farooq, Z., Mahr, M.S.
  • Journal    : Solar Energy,
  • Year         :2024

Linking the increasing epidemiology of scrub typhus transmission in India and South Asia: are the varying environment and the reservoir animals the factors behind?

  • Authors   : Mohapatra, R.K., Al-Haideri, M., Mishra, S., … Mohanty, A., Sah, R.
  • Journal    :Frontiers in Tropical Diseases,
  • Year         :2024

Prof. Rasha Azzam|Drug Discovery and Development|Best Researcher Award

Published on by Top Pharmaceutical

Prof. Rasha Azzam|Drug Discovery and Development |Best Researcher Award

Prof. Rasha Azzam at Helwan University,Egypt

PROFILE  

orcid

Early Academic Pursuits 🎓

Prof. Rasha A. Azzam’s academic journey began with her outstanding performance in chemistry at Helwan University, Egypt, where she graduated with a Bachelor of Science (B.Sc.) in Chemistry in 1993. Her excellence in academia was recognized early on, as she graduated with class honors and was placed on the Dean’s List. Driven by her passion for organic chemistry, she pursued a Master of Science (M.Sc.) degree in Organic Chemistry at Helwan University, completing it in 1996. Her academic curiosity and dedication led her to further her studies internationally, earning a prestigious Ph.D. in Organic Chemistry in 2003 from the Catholic University of Leuven in Belgium. Her diverse educational background laid the foundation for a career defined by groundbreaking research and academic excellence.

Professional Endeavors 🧑‍🔬

Prof. Azzam’s professional career spans over two decades of teaching, research, and leadership in various prestigious academic institutions across the globe. She is currently a Professor of Organic Chemistry at the Faculty of Science, Helwan University, where she has been contributing since 2021. Prior to this, she held the position of Associate Professor of Organic Chemistry at the same institution from 2016 to 2021, demonstrating her upward trajectory in academia.

Her teaching and research influence extended beyond Egypt. She has held positions as an Associate Professor at Taibah University in Saudi Arabia, Nigerian Turkish Nile University in Nigeria, and the American University in Nigeria, where she was a co-founder of the Petroleum Chemistry Program. Additionally, she has served as a Visiting Professor at Virginia Commonwealth University in 2024, further showcasing her international academic reach.

Contributions and Research Focus 🔬

Prof. Azzam’s research focuses on organic and medicinal chemistry, with a particular emphasis on green synthesis, nanomaterials, and antiviral agents. One of her key research interests is the development of new methods for synthesizing compounds with potential anticancer and antimicrobial properties. Her recent project, “Synthesis of new sulfa derivatives under ultrasonic irradiation as potential anticancer/antimicrobial agents,” funded by Helwan University in 2021, highlights her innovative approach to organic synthesis.

Prof. Azzam’s work also explores environmentally friendly technologies, as demonstrated by her research on “green technology based on nanoporous biodegradable polymeric membranes” for wastewater treatment, funded by the Academy of Scientific Research Technology (ASRT). She has also conducted pioneering work on nanomaterials and their applications in industrial processes, such as her research on thermoplastic elastomers based on petrochemicals and the development of anti-COVID-19 agents incorporated into nanofibrous mats.

Her research output is extensive, and she has presented several projects on global platforms, including her work on antiviral therapeutic agents and nanomaterials. Her research contributions are shaping the future of organic chemistry, particularly in the domains of green chemistry and medical applications.

Accolades and Recognition 🏆

Prof. Azzam’s excellence in research and community service has been recognized through numerous awards and honors. In 2023, she received the prestigious Prince Mohammed Bin Fahd Scientific Award for her contributions to scientific production that serves community development within the framework of sustainable development goals. In the same year, she was honored with Helwan University’s Outstanding Scientific Achievement Award in Basic and Applied Sciences.

She has also been recognized for her mentoring and supervision of students, receiving Best Master Thesis Awards for two of her master’s students, Rasha Essam (2020) and Heba Elboshi (2023). Her commitment to advancing research was further acknowledged when she received the Research Excellence Awards for her students, Rokia Ramadan (2019) and Rasha Essam (2020). Additionally, Prof. Azzam was awarded a Silver Medal from the Academy of Scientific Research Technology (ASRT) in 2018 for her outstanding contributions to science.

Her impact extends internationally, with her receiving the Outstanding Faculty Member Award from the American University in Nigeria in 2007, and a research scholarship from the Catholic University of Leuven in 2001.

Impact and Influence 🌍

Prof. Azzam’s influence is felt not only through her research but also through her active participation in the scientific community. She serves as a Review Editor for Organic Chemistry on the Editorial Board of Frontiers in Chemistry and as an editor for the Journal of Chemistry and The Scientific World Journal, both published by Hindawi. She is also a grant evaluator for the Fulbright Binational Scholarship Program, where she helps assess the next generation of academic leaders.

Her commitment to education and community service is reflected in her involvement in organizing training workshops for high school teachers and instructing lab sessions for the AUN Community School. Prof. Azzam is also a member of the Egyptian Society for Basic Sciences, where she contributes to the development of the scientific community in Egypt.

Legacy and Future Contributions 🌟

Prof. Rasha A. Azzam’s legacy is built on her unwavering dedication to advancing organic chemistry, fostering academic excellence, and mentoring the next generation of scientists. Her research has laid the groundwork for significant developments in green chemistry, nanomaterials, and medicinal chemistry. With her continued focus on innovative solutions for pressing global challenges, such as wastewater treatment and the development of antiviral agents, she is poised to make even more impactful contributions in the years to come.

🎓Publication 

In the pursuit of novel therapeutic agents: synthesis, anticancer evaluation, and physicochemical insights of novel pyrimidine-based 2-aminobenzothiazole derivatives

  • Authors   :Toka I. Ismail; Nashwa El-Khazragy; Rasha A. Azzam
  • Journal    :RSC Advances
  • Year         :2024

Novel High-Performance Functionalized and Grafted Bio-Based Chitosan Adsorbents for the Efficient and Selective Removal of Toxic Heavy Metals from Contaminated Water

  • Authors   :Mohammad Monir; Rasha E. Elsayed; Rasha Azzam; Tarek M. Madkour
  • Journal    :Polymers
  • Year         :2024

Crystal structure of 4-(benzo[d]thiazol-2-yl)-1,2-dimethyl-1H-pyrazol-3(2H)-one

  • Authors   :Heba A. Elboshi; Rasha A. Azzam; Galal H. Elgemeie; Peter G. Jones
  • Journal    :Acta Crystallographica Section E Crystallographic Communications
  • Year         :2024

Synthesis of New Guanidine Benzothiazole Derivative and Its Application as Eco-Friendly Corrosion Inhibitor

  • Authors   : Abdel-karim, Amal M.; Azzam, Rasha A.; Shehata, Omnia S.; Adly, Mohamed A.; El-Shamy, Omnia A. A.; El-Mahdy, Gamal A.
  • Journal    :Chemistry
  • Year         :2023

Crystal structure of 2-{[5-(methylsulfanyl)-4-phenyl-4H-1,2,4-triazol-3-yl]methyl}benzo[d]thiazole

  • Authors   : Rasha A. Azzam; Galal H. Elgemeie; Heba A. Elboshi; Peter G. Jones
  • Journal    :Crystallographica Section E Crystallographic Communications
  • Year         :2023